Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual ...

ProBio, a global contract development and manufacturing organization (CDMO), announced that it will present six poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th ...

Arvinas to present preclinical data for PROTAC BCL6 degrader & ARV-393 at 2025 AACR annual meeting in Chicago: New Haven, Connecticut Wednesday, April 23, 2025, 18:00 Hrs [IST] Ar ...

Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today announced that the company’s abstract featuring clinical trial ...

Less than 24 hours ago, u/ChipsNoDip shared a screenshot of DNA test results captioned: "Thought it'd be fun to get a test, now it isn't," as the results referred to their sisters as "half" siblings.

Ninety posters and presentations at AACR powered by the Standard BioTools proteomic portfolio to advance cancer research from target discovery to clinical development ...

ARV-393 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas.

A Reddit user was shocked by DNA ... original poster replied: "Math checks out!" Other users have shared similar stories and sent sympathetic messages. Newsweek reached out to biotechnology ...

"Elraglusib with chemotherapy and immune priming represents a novel sequential therapy approach to treat advanced salivary ...